HOME >> MEDICINE >> NEWS
Stanford researchers identify immune dysfunction in melanoma patients

STANFORD, Calif. -- Researchers at the Stanford University School of Medicine have begun to shed light on why the human immune system isn't able to stop such cancers as melanoma, suggesting answers that could pave the way for better treatment of this often-fatal illness.

In a small study, the scientists found that the immune cells in a majority of people with this deadly skin cancer fail to respond properly to a molecule called interferon, which normally activates the immune system. Without the ability to respond to interferon, the cells are less able to fend off the cancer, according to the study that will be published in the May issue of Public Library of Science-Medicine.

These results help explain a decade of research showing that people with cancer often have dysfunctional immune systems. Until now, researchers could tell that the immune system wasn't working properly but didn't know which genes or pathways were involved in that failure. Finding the disruption in the cancer cells' interferon response could help in the development of vaccines to treat cancers.

"We think this is a dominant way that immune dysfunction occurs in people with cancer," said senior author Peter Lee, MD, associate professor of medicine.

Lee was interested in melanoma rather than other forms of cancer in part because of the deadly nature of the disease, which will kill about one in six of the 47,700 people it is expected to strike this year. Unless melanoma is caught early and removed, there is no effective treatment, although research groups have been testing vaccine therapies for the disease. However, Lee worried that unless researchers better understood immune dysfunctions in those people, the vaccines would have a low probability of success. "If you don't address the underlying immune defects, then vaccines won't do any good," Lee said.

The group started by separating out the four major types of immune cells from people with melano
'"/>

Contact: Amy Adams
amyadams@stanford.edu
650-723-3900
Stanford University Medical Center
7-May-2007


Page: 1 2 3

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. Old McDonalds has a hold on kids taste buds, Stanford/Packard study finds
3. Aging stem cells in mice may hold answers to diseases of the aged, Stanford study finds
4. Stanford researchers track human stem cells transplanted into rat brain
5. Once-fatal metabolic disorders treatable, says Stanford/Packard researcher
6. Tiny newborns face higher risk of death at community hospitals, Stanford/VA study finds
7. Star Trek-type scanning may reveal genetic activity of tumors, Stanford study shows
8. Scavenger cells may have role blocking obesity, Stanford study shows
9. Eye diseases gave great painters different vision of their work, Stanford ophthalmologist says
10. IADR presents Research in Prosthodontics & Implants Award to Stanford
11. Insight on fruit fly immune system could lead to new types of vaccines, Stanford researchers say

Post Your Comments:
(Date:8/1/2015)... , ... August 01, 2015 , ... On Tuesday, July ... , who are thought to have been behind the attack on Anthem Inc. which ... were zero day exploits, watering hole attacks and spear phishing campaigns. , ...
(Date:7/31/2015)... ... July 31, 2015 , ... That’s ... What are the STASH awards? The Significant Technological Achievements in Secretive Horticulture (or ... as well as tried-and-true products that have stood the test of time. These ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reliable source ... in Chicago at Grant Park. The festival will end on Sunday, August 2nd. ... Chicago for the annual Lollapalooza. This unique and unbelievably popular festival attracts the ...
(Date:7/31/2015)... ... ... Sculpted Contours Luxury Medical Aesthetics announces the arrival of the newest applicator for ... applicator in the United States as an upgrade to the CoolSmooth applicator cleared by ... required a 2 hour treatment time. The new CoolSmooth Pro reduces the treatment ...
(Date:7/31/2015)... ... July 31, 2015 , ... M3 USA MDLinx.com, source ... launch three new Board Exam Courses. , The additions of Gastroenterology, Pulmonology and ... Prep from MDLinx makes preparing for the exam easy and painless. MDLinx offers ...
Breaking Medicine News(10 mins):Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3
(Date:7/31/2015)... July 31, 2015 Egalet Corporation (Nasdaq: ... pharmaceutical company focused on developing, manufacturing and marketing ... its previously announced underwritten public offering of 7,666,667 ... offering price of $11.25 per share. The shares ... shares issued upon the exercise in full by ...
(Date:7/31/2015)... WOODCLIFF LAKE, N.J. and SAN ... announced today that its parent company Eisai Co., Ltd. ... Haruo Naito , "Eisai") and Halozyme Therapeutics, Inc. ... and CEO: Dr. Helen Torley , "NASDAQ: HALO") ... eribulin mesylate (brand name: Halaven ® , "eribulin") in ...
(Date:7/31/2015)... , July 31, 2015 According ... Market by Product (Bioimpedance Analyzers (BIA), Dual-Energy X-ray Absorptiometry ... Weighing) - Global Analysis & Forecast to 2019", published ... pegged at $911.1 Million 2014 and is estimated to ... CAGR of 9.4% from 2014 to 2019. ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4
Cached News: